Abstract
To compare the therapeutic effect of rimonabant, a new drug which is a selective antagonist of CB1 receptors, with the sibutramine. It is an experimental clinical trial, prospective, placebo controlled. Our test was performed in 38 rats, adults females with a hyper caloric diet. We collected their blood 3 times and weighted them once a week. We divided the rats in 3 groups: Rimonabant, Sibutramine and Control. Statistic analysis has been made through ANOVA test, Tukey test and t Student test. The Rimonabant group demonstrated a significant reduction of the weight increase in rats. The Sibutramine group showed a significant reduction on blood glycemia compared to Rimonabant group and Control group. Rimonabant showed to be more effective than Sibutramine by decreasing weight gain. Sibutramine has been more effective than Rimonabant and Control groups by decreasing the blood glycemia.
Highlights
World Health Organization classifies obesity as a global epidemic
This study aims to compare Rimonabant and Sibutramine effects in food intake and weight loss of rats and to determinate the effects of these drugs on lipid and glycide profile
Comparison of rimonabant and sibutramine treatment effects on food compulsion in rats pressuring in circles to tear the orbital cavity membrane
Summary
For the first time in history, the number of people over weight has passed the number of those who are malnutrited (one billion and two hundred million in the world). Countries that were recently concerned with hunger and food scarceness already present an alarming increase of obese people. Obesity was considered a problem of wealthy people. As misery is being eradicated among low budget populations, obesity arises as the most frequent and important public health problem and even more serious than malnutrition[1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
